Merck puts $1.3bn into AI via Exscientia, BenevolentAI deals

Exscientia wants to bring its AI/ML approach into the world of biologics. It's starting with antibodies

Exscientia is looking at breaking out of small molecule R&D. The UK biotech announced Thursday that it is expanding its R&D efforts into biologics, more specifically antibodies, looking to implement precision engineering and utilize in silico screening. And in order to put the expansion into place, Exscientia also announced that